| Proteome-based plasma biomarkers for Alzheimer's disease A Hye, S Lynham, M Thambisetty, M Causevic, J Campbell, HL Byers, ... Brain 129 (11), 3042-3050, 2006 | 585 | 2006 |
| Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease M Thambisetty, A Simmons, L Velayudhan, A Hye, J Campbell, Y Zhang, ... Archives of general psychiatry 67 (7), 739-748, 2010 | 487 | 2010 |
| Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor LJ Barber, S Sandhu, L Chen, J Campbell, I Kozarewa, K Fenwick, ... The Journal of pathology 229 (3), 422-429, 2013 | 383 | 2013 |
| Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance SJ Pettitt, DB Krastev, I Brandsma, A Dréan, F Song, R Aleksandrov, ... Nature communications 9 (1), 1849, 2018 | 373 | 2018 |
| Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity I Bajrami, JR Frankum, A Konde, RE Miller, FL Rehman, R Brough, ... Cancer research 74 (1), 287-297, 2014 | 369 | 2014 |
| ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A CT Williamson, R Miller, HN Pemberton, SE Jones, J Campbell, A Konde, ... Nature communications 7 (1), 13837, 2016 | 329 | 2016 |
| Unbiased analysis of potential targets of breast cancer susceptibility loci by Capture Hi-C NH Dryden, LR Broome, F Dudbridge, N Johnson, N Orr, S Schoenfelder, ... Genome research 24 (11), 1854-1868, 2014 | 277 | 2014 |
| High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical Trial A Pearson, E Smyth, IS Babina, MT Herrera-Abreu, N Tarazona, C Peckitt, ... Cancer discovery 6 (8), 838-851, 2016 | 262 | 2016 |
| A genetic screen using the PiggyBac transposon in haploid cells identifies Parp1 as a mediator of olaparib toxicity SJ Pettitt, FL Rehman, I Bajrami, R Brough, F Wallberg, I Kozarewa, ... PloS one 8 (4), e61520, 2013 | 187 | 2013 |
| Efficacy of chemotherapy in BRCA1/2 mutation carrier ovarian cancer in the setting of PARP inhibitor resistance: a multi-institutional study JE Ang, C Gourley, CB Powell, H High, R Shapira-Frommer, ... Clinical Cancer Research 19 (19), 5485-5493, 2013 | 151 | 2013 |
| Plasma biomarkers of brain atrophy in Alzheimer's disease M Thambisetty, A Simmons, A Hye, J Campbell, E Westman, Y Zhang, ... PloS one 6 (12), e28527, 2011 | 138 | 2011 |
| Parallel RNA Interference Screens Identify EGFR Activation as an Escape Mechanism in FGFR3-Mutant Cancer MT Herrera-Abreu, A Pearson, J Campbell, SD Shnyder, MA Knowles, ... Cancer discovery 3 (9), 1058-1071, 2013 | 132 | 2013 |
| Large-scale profiling of kinase dependencies in cancer cell lines J Campbell, CJ Ryan, R Brough, I Bajrami, HN Pemberton, IY Chong, ... Cell reports 14 (10), 2490-2501, 2016 | 121 | 2016 |
| E-cadherin/ROS1 inhibitor synthetic lethality in breast cancer I Bajrami, R Marlow, M van de Ven, R Brough, HN Pemberton, J Frankum, ... Cancer discovery 8 (4), 498-515, 2018 | 109 | 2018 |
| Elevated APOBEC3B expression drives a kataegic-like mutation signature and replication stress-related therapeutic vulnerabilities in p53-defective cells J Nikkilä, R Kumar, J Campbell, I Brandsma, HN Pemberton, F Wallberg, ... British journal of cancer 117 (1), 113-123, 2017 | 103 | 2017 |
| CDK1 is a synthetic lethal target for KRAS mutant tumours S Costa-Cabral, R Brough, A Konde, M Aarts, J Campbell, E Marinari, ... PloS one 11 (2), e0149099, 2016 | 101 | 2016 |
| Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib RE Miller, R Brough, I Bajrami, CT Williamson, S McDade, J Campbell, ... Molecular cancer therapeutics 15 (7), 1472-1484, 2016 | 97 | 2016 |
| Proteome-based plasma markers of brain amyloid-β deposition in non-demented older individuals M Thambisetty, R Tripaldi, J Riddoch-Contreras, A Hye, Y An, J Campbell, ... Journal of Alzheimer's Disease 22 (4), 1099-1109, 2010 | 91 | 2010 |
| Poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of advanced germline BRCA2 mutant prostate cancer SK Sandhu, A Omlin, L Hylands, S Miranda, LJ Barber, R Riisnaes, ... Annals of oncology 24 (5), 1416-1418, 2013 | 89 | 2013 |
| Plasma gelsolin is decreased and correlates with rate of decline in Alzheimer's disease A Güntert, J Campbell, M Saleem, DP O'Brien, AJ Thompson, HL Byers, ... Journal of Alzheimer's Disease 21 (2), 585-596, 2010 | 87 | 2010 |
Christopher LordProfessor of Cancer Genomics, Institute of Cancer Research, London, UK在 icr.ac.uk 的电子邮件经过验证
